טוען...
CRISPR/Cas9 gene editing for curing sickle cell disease
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic...
שמור ב:
| הוצא לאור ב: | Transfus Apher Sci |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049447/ https://ncbi.nlm.nih.gov/pubmed/33455878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.transci.2021.103060 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|